Drug Trial Radar · NCT07201922
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
May 14, 2029
Study completion May 23, 2029
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis. Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo. Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months. Doctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.
Conditions
- Familial Pulmonary Fibrosis
- Interstitial Lung Abnormalities
- Interstitial Lung Diseases
Interventions
NerandomilastDrug
Nerandomilast
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to physiologic or radiologic worsening of ILA/ILD over the whole trialTime frame: up to 164 weeks
Locations
55 sites in 13 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California · Not yet recruiting
University of Colorado Denver
Aurora, Colorado · Recruiting
Clinical Research Specialists LLC - Kissimmee
Kissimmee, Florida · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Weill Cornell Medicine-New York-60569
New York, New York · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Centro de Investigaciones Metabolicas (CINME)
Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires
CABA, Argentina · Recruiting
Fundacion NIBA Neurologia Infantil Buenos Aires
CABA, Argentina · Recruiting
Centro de Investigacion Clinica Belgrano
CABA, Argentina · Recruiting
Consultorios Medicos del Buen Ayre
Capital Federal, Argentina · Recruiting
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
Lung Research Queensland
Chermside, Queensland, Australia · Recruiting
The Prince Charles Hospital
Chermside, Queensland, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada · Recruiting
McGill University Health Centre (MUHC)
Montreal, Quebec, Canada · Recruiting
Hopital Louis Pradel
Bron, France · Recruiting
INS Coeur Poumon
Lille, France · Recruiting
HOP Bichat
Paris, France · Recruiting
HOP Pontchaillou
Rennes, France · Recruiting
Hôpital Larrey - CHU de Toulouse
Toulouse, France · Recruiting
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
Essen, Germany · Recruiting
Medizinische Hochschule Hannover
Hanover, Germany · Recruiting
Lungenfachklinik Immenhausen
Immenhausen, Germany · Recruiting
Krankenhaus Bethanien gGmbH
Solingen, Germany · Recruiting
IRCCS MultiMedica
Milan, Italy · Recruiting
Azienda Ospedaliera Universitaria di Padova
Padova, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Recruiting
Tosei General Hospital
Aichi, Seto, Japan · Recruiting
Tsuboi Hospital
Fukushima, Koriyama, Japan · Recruiting
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.